Skip to main content
. Author manuscript; available in PMC: 2016 Mar 15.
Published in final edited form as: J Immunol. 2015 Feb 13;194(6):2942–2953. doi: 10.4049/jimmunol.1402610

Figure 6. Exogenous TGFβ1 increases viability of BZ-treated CTCL cells.

Figure 6

HH cells were transfected with control (full columns) or TGFβ1 specific (empty columns) siRNA, incubated 24 hours with 0, 200 and 400 pg/ml of exogenously added recombinant TGFβ1 protein, and analyzed for cell viability (A), cytoplasmic nucleosome enrichment (B), and IL-8 mRNA levels (C). (D) Viability of Hut-78, H9, HH, and PBMC cells incubated 24 hours with increasing amounts of exogenously added TGFβ1 protein, in the presence of 100 nM BZ. The values in Figs. 6A–D represent the mean +/−SE of four experiments; asterisks denote a statistically significant (p<0.05) change compared to corresponding cells incubated without exogenously added TGFβ1. (E) Western blotting of whole cell extracts (WCE) prepared from untreated Hut-78, H9, HH, and PBMC cells, and analyzed by using TβRI, TβRII, and control actin antibodies. (F) Western analysis of TβRI and TβRII protein levels in WCE of HH cells transfected with TβRI, TβRII, or control siRNA. (G) Cell viability and (H) nucleosome enrichment analyzed in HH cells transfected with TβRI, TβRII, or control siRNA, and incubated 24 hours with 0, 200 and 400 pg/ml of exogenously added TGFβ1. The values in Figs. 6G and H represent the mean +/−SE of four experiments. Asterisks denote a statistically significant change compared to cells transfected with the corresponding control siRNA.